Red Nucleus Turns Green Following THL Acquisition
Search

Red Nucleus Turns Green Following THL Acquisition

THL's investment in Red Nucleus was made through its $5.6 billion ninth fund which closed in October 2021

Red Nucleus provides learning and development services, including training programs designed for pharmaceutical sales teams, clinical staff, and healthcare professionals.

SOURCE: Getty Images

THL Partners has made a majority equity investment in Red Nucleus, a provider of specialized services to life sciences companies.

Red Nucleus provides learning and development services, including training programs designed for pharmaceutical sales teams, clinical staff, and healthcare professionals. These programs use e-learning modules, workshops, and interactive tools to simplify and communicate complex scientific information. In the area of medical and scientific communications, Red Nucleus assists clients in producing scientific content, such as clinical study reports, peer-reviewed publications, regulatory submissions, and educational materials.

Additionally, Red Nucleus supports pharmaceutical companies with market access and commercialization strategies, helping them develop effective pricing and reimbursement plans. This includes navigating healthcare system complexities to ensure successful product launches and adoption by addressing the requirements of payers and healthcare providers.

Red Nucleus has more than 200 global customers, including biotech startups and pharmaceutical companies. The company, with more than 700 employees, was founded in 1991 by Ian Kelly and is headquartered 30 miles northeast of Philadelphia in Yardley, Pennsylvania, with 11 additional offices in the United States (4), Canada, Costa Rica, the United Kingdom, Switzerland, Morocco, India, and Japan.

In a moment when scientific breakthroughs are contributing to the production of life-saving and life-changing therapies, the mission at Red Nucleus could not be more critical.

With the closing of the transaction, Mike Menta has been named the new CEO of Red Nucleus. Mr. Menta is the former head of the consulting and enterprise solutions divisions of Syneos Health, a North Carolina-headquartered provider of clinical development and drug commercialization support services to biopharmaceutical companies. Additionally, Mr. Kelly will now assume the role of Chief Relationship Officer and will also serve as Vice Chairman of the Board of Directors.

“With Mike Menta at the helm, and Ian Kelly in an important new leadership role, Red Nucleus is uniquely positioned for success,” said Megan Preiner, a managing director at THL. “Mike’s two decades of work in clinical, medical, and commercial roles establish him as a recognized leader in pharmaceutical commercialization, and Ian’s industry knowledge and deep customer affinity make him an invaluable part of the company’s next growth stage. It’s the right team, for the right company, at the right moment.”

“When I founded Red Nucleus, I had a vision to fill a critical gap in the pharmaceutical value chain,” said Mr. Kelly. “I’m proud of the work we’ve done for our customers and the very real impact we’ve had on the lives of patients, and I’m thrilled to partner with Mike Menta as we build on this strong foundation and expand that impact in the years to come.”

“In a moment when scientific breakthroughs are contributing to the production of life-saving and life-changing therapies, the mission at Red Nucleus could not be more critical,” said Mr. Menta. “The company is instrumental in helping its customers move new molecules to market. We have a unique opportunity to broaden and deepen that work, and I could not be more excited to work with such a talented and dedicated team of professionals.”

THL was founded in 1974 and is one of the oldest private equity investment firms in the United States. Industries of interest include financial services, healthcare, and technology & business solutions. Since its founding, Boston-based THL has raised over $35 billion of equity capital, acquired over 170 portfolio companies, and completed over 600 add-on acquisitions.

THL’s investment in Red Nucleus was through its ninth fund, Thomas H. Lee Equity Fund IX LP, which closed in October 2021 with $5.6 billion in committed capital.

© 2024 Private Equity Professional | October 23, 2024

To search in site, type your keyword and hit enter